Ixazomib

0:11:40

All About Ninlaro (Ixazomib) #myeloma

0:04:47

TOURMALINE-MM4: oral ixazomib maintenance for myeloma

0:00:58

The efficacy of ixazomib for the treatment of R/R myeloma

0:06:07

Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

0:01:56

Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma

0:01:55

Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

0:02:54

TOURMALINE-MM4: oral ixazomib maintenance for myeloma

0:01:04

Dr. Kumar on Ixazomib Combo for Multiple Myeloma Treatment

0:01:26

Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis

0:04:23

IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma

0:04:19

TOURMALINE-MM3 and 4: Ixazomib as Maintenance Therapy in Myeloma Patients

0:01:36

TOURMALINE-AL1: ixazomib-dexamethasone for AL amyloidosis

0:02:38

DARIA: daratumumab with ixazomib and dexamethasone for R/R myeloma

0:10:55

Patient Selection for Ixazomib in Myeloma

0:09:48

Ixazomib and Elotuzumab in Multiple Myeloma

0:01:49

Real world data of ixazomib in combination with lenalidomide and dexamethasome

0:08:12

Effectiveness and Safety of Ixazomib-Based Therapy in RRMM Outside of A Clinical Trial: UVEA IXA

0:03:55

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

0:02:22

Dr. Voorhees on Pomalidomide/Dexamethasone/Ixazomib Triplet in Multiple Myeloma

0:01:44

Prevention of progression: ixazomib/len/dex in high-risk SMM

0:00:55

The value of ixazomib in the treatment of older, frail patients with multiple myeloma

0:06:52

Ixazomib Extends PFS in the TOURMALINE-MM1 Trial

0:08:07

EU Approval of Ixazomib for Relapsed/Refractory Myeloma

0:05:45

Ixazomib-based therapy for R/R myeloma in the real-world setting